We also investigated the impact of targeting myeloid cell checkpoints together with T cell checkpoints on tumor growth by using anti-IL1B, anti-TREM2 or anti-IFITM, alone or in combination with anti-PD-1/CTLA4/LAG3. Here, PDCD1 is linked to neoplasm.